Inflammation is part of the body’s natural healing process, but when it gets out of control it can cause disease. Monash Institute of Pharmaceutical Sciences (MIPS) researchers, in collaboration with researchers from the
Bob Blouin, Dean of Eshelman School of Pharmacy, University of North Carolina at Chapel Hill, receives honorary degree from Monash University
In a graduation ceremony earlier today, Monash University has conferred an honorary doctorate upon Professor Robert A. “Bob” Blouin, Dean of the UNC Eshelman School of Pharmacy at the University of North Carolina (UNC) at Chapel Hill.
Monash University drug discovery research has led to a change in editorial policy of the world’s largest scientific society, in a move that could save government and industry millions of dollars a year in preventing dead-end research.
Researcher from the Monash Institute of Pharmaceutical Sciences elected to the Australian National Academy of Science
Professor Thomas Davis has been elected as a Fellow of The Australian National Academy of Science. Professor Davis is an internationally renowned polymer chemist and nanotechnologist.
World-leading pharmaceutical sciences researcher Professor Chris Porter has been appointed Director of the Monash Institute of Pharmaceutical Sciences (MIPS), effective from 3 April 2017.
In a paper published today in the influential journal Nature, researchers from the Monash Institute of Pharmaceutical Sciences (MIPS) at Monash University discuss the use of a novel technique to reveal the structure of an important drug target.
The Monash University Institute of Pharmaceutical Sciences (MIPS) today announced positive results from a first-in-human study of a new, inhaled form of a medicine that could significantly reduce maternal deaths around the world.
The image of an unhealthy person chowing down on a burger and fries one minute then gobbling anti-cholesterol medication in the hope of atoning for their dietary sins is staple of popular culture. But a new study from Monash University researchers